MP48-14 ONCE DAILY ADMINISTRATION OF UDENAFIL 50MG AND 75MG SAFELY IMPROVES ERECTILE DYSFUNCTION: THE OUTCOME FROM A PHASE III MULTICENTER RANDOMIZED DOUBLE-BLIND CLINICAL TRIAL

2014 ◽  
Vol 191 (4S) ◽  
Author(s):  
Phil Hyun Song ◽  
Young-Hwii Ko ◽  
Yoon Seob Ji ◽  
Bong Gi Ok ◽  
Ki Hak Moon ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Erectile Dysfunction ◽  
Daily Administration ◽  
Phase Iii ◽  
Double Blind ◽  
Once Daily ◽  
Double Blind Clinical Trial

A Double-Blind Clinical Comparison of Two Dosage Schedules of Cefatrizine in Children

1988 ◽  
Vol 16 (3) ◽  
pp. 197-200
Author(s):  
P. Careddu ◽  
G. Ceccarelli
Keyword(s):  
Clinical Trial ◽  
Respiratory Tract ◽  
Bacterial Infection ◽  
Randomized Clinical Trial ◽  
Clinical Symptoms ◽  
Daily Administration ◽  
Bacterial Eradication ◽  
Double Blind ◽  
Once Daily ◽  
Clinical Comparison

A double-blind, randomized clinical trial was carried out to compare the effectiveness of twice daily versus once daily administration of the cephalosporin, cefatrizine, in paediatric outpatients with bacterial infection of the respiratory tract. Thirty children were studied, aged 7 years 2 months (range, 4–-12 years). They were given 75 mg/kg·day cefatrizine either once daily or twice daily at 12 h intervals for 8 days. Fever, clinical symptoms, bacterial eradication and overall tolerance were evaluated. No significant differences were observed between once daily or twice daily administration. This is in agreement with other studies carried out on adults. It is concluded that cefatrizine may be given to paediatric out-patients for the treatment of bacterial infection of the respiratory tract only once daily with good clinical and overall results.

scholarly journals A Random-Assignment, Double-Blind, Clinical Trial of Once- vs Twice-Daily Administration of Quetiapine Fumarate in Patients with Schizophrenia or Schizoaffective Disorder: A Pilot Study

2003 ◽  
Vol 48 (3) ◽  
pp. 187-194 ◽  
Author(s):  
KN Roy Chengappa ◽  
Haranath Parepally ◽  
Jaspreet S Brar ◽  
Jamie Mullen ◽  
Ann Shilling ◽  
...  
Keyword(s):  
Orthostatic Hypotension ◽  
Schizoaffective Disorder ◽  
A Priori ◽  
Daily Administration ◽  
Double Blind ◽  
Safety Measures ◽  
Once Daily ◽  
Adult Men ◽  
Double Blind Clinical Trial ◽  
Double Blind Design

Objective: To evaluate the efficacy and safety of administering quetiapine once vs twice daily. Method: Utilizing a double-blind design, 21 hospitalized adult men or women with DSM-IV schizophrenia or schizoaffective disorder, who had received unchanged doses (for 2 weeks) of either 400 or 600 mg daily of quetiapine administered in 2 doses, were randomly assigned to once- or twice-daily administration for 4 weeks and then crossed over to the opposite dosing regimen for an additional 4 weeks. Standard psychopathology and safety measures were used in the study. Results: Nearly 70% (15/21) of the subjects met the a priori efficacy responder criteria with no statistical differences in response between those assigned to once- or twice-daily quetiapine administration. Statistical analyses confirmed that most subjects maintained efficacy during the switch to once- or twice-daily administration with quetiapine. A minority (15%) did experience worsening of symptoms or orthostatic hypotension during the crossover. Quetiapine was generally well tolerated at either twice- or once-daily administration. Conclusions: These pilot data suggest that it is clinically feasible to switch most quetiapine-treated subjects receiving a therapeutic twice-daily dosing schedule to a once-daily regimen. A minority may experience worsening of symptoms or orthostatic hypotension during the switch. This strategy of administering quetiapine entirely at bedtime may promote improved adherence to treatment.

Sign in / Sign up

Export Citation Format

Share Document